Fritzgerald Leveque
North Shore-LIJ Health System
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Fritzgerald Leveque.
The Journal of Nuclear Medicine | 2017
Kenneth Nichols; William Robeson; Miyuki Yoshida-Hay; Pat Zanzonico; Fritzgerald Leveque; Kuldeep K. Bhargava; Gene Tronco; Christopher J. Palestro
To protect bone marrow from overirradiation, the maximum permissible activity (MPA) of 131I to treat thyroid cancer is that which limits the absorbed dose to blood (as a surrogate of marrow) to less than 200 cGy. The conventional approach (method 1) requires repeated γ-camera whole-body measurements along with blood samples. We sought to determine whether reliable MPA values can be obtained by simplified procedures. Methods: Data acquired over multiple time points were examined retrospectively for 65 thyroid cancer patients, referred to determine 131I uptake and MPA for initial treatment after thyroidectomy (n = 39), including 17 patients with compromised renal function and 22 patients with known (n = 16) or suspected (n = 6) metastases. The total absorbed dose to blood (DTotal) was the sum of mean whole-body γ-ray dose component (Dγ) from uncollimated γ-camera measurements and dose due to β emissions (Dβ) from blood samples. Method 2 estimated DTotal from Dβ alone, method 3 estimated DTotal from Dγ alone, and method 4 estimated DTotal from a single 48-h γ-camera measurement. MPA was computed as 200 cGy/DTotal for each DTotal estimate. Results: Method 2 had the strongest correlation with conventional method 1 (r = 0.98) and values similar to method 1 (21.0 ± 13.7 cGy/GBq vs. 21.0 ± 14.1 cGy/GBq, P = 0.11), whereas method 3 had a weaker (P = 0.001) correlation (r = 0.94) and method 4 had the weakest (P < 0.0001) correlation (r = 0.69) and lower dose (16.3 ± 14.8 cGy/GBq, P < 0.0001). Consequently, correlation with method 1 MPA was strongest for method 2 MPA (r = 0.99) and weakest for method 4 (r = 0. 75). Method 2 and method 1 values agreed equally well regardless of whether patients had been treated with 131I previously or had abnormal renal function. Conclusion: Because MPA based on blood measurements alone is comparable to MPA obtained with combined body counting and blood sampling, blood measurements alone are sufficient for determining MPA.
The Journal of Nuclear Medicine | 2018
Fritzgerald Leveque; Jeanine Drury; Xiyao Zhao; Maria-Bernadette Tomas; Christopher J. Palestro; Kenneth Nichols
The Journal of Nuclear Medicine | 2015
Kuldeep K. Bhargava; Kenneth Nichols; Fritzgerald Leveque; Sanjeev Gupta; Christopher J. Palestro
The Journal of Nuclear Medicine | 2015
Peter Kamvosoulis; Fritzgerald Leveque; Maria-Bernadette Tomas; Kenneth Nichols; Christopher J. Palestro
Society of Nuclear Medicine Annual Meeting Abstracts | 2014
Alex Zaharakis; Fritzgerald Leveque; Jacek Backiel; Grace Tursi; Christopher Palestro; Kenneth Nichols
Society of Nuclear Medicine Annual Meeting Abstracts | 2014
Kenneth Nichols; Maria-Bernadette Tomas; Fritzgerald Leveque; Christopher Palestro
The Journal of Nuclear Medicine | 2013
Fritzgerald Leveque; Kuldeep K. Bhargava; Paul Pugliese; Kenneth Nichols; Christopher J. Palestro
Society of Nuclear Medicine Annual Meeting Abstracts | 2013
Kenneth Nichols; Maria-Bernadette Tomas; Fritzgerald Leveque; Christopher Palestro
The Journal of Nuclear Medicine | 2012
Fritzgerald Leveque; Paul Pugliese; Maria B. Tomas; Jaimie Kim; Kenneth Nichols; Christopher J. Palestro
Society of Nuclear Medicine Annual Meeting Abstracts | 2012
Kenneth Nichols; Maria Tomas; Leonardo Rivera; Fritzgerald Leveque; Christopher Palestro